AbbVie’s Rinvoq gains updated indication for ulcerative colitis, Crohn’s

AbbVie (NYSE:ABBV) said that the US FDA has updated the indication for its JAK inhibitor Rinvoq (upadacitinib) to allow individuals with ulcerative colitis or Crohn’s disease to be given the treatment after having received at least one approved systemic therapy in the event TNF blockers are clinically inadvisable.
Prior, the indication for ulcerative colitis and Crohn’s was for those with an inadequate response or intolerance to one or more TNF blockers.